Medical Access and Reimbursement in Mexico

Psilocybin, psilocin, and hallucinogenic mushrooms are Group I psychotropics under Mexico's General Health Law. Article 249 limits the acquisition of Group I substances to health-authority-authorised scientific research, so this is not a routine medical pathway. #

MDMA is treated as a high-control psychotropic in Article 245. No Mexican market authorisation or routine reimbursement route was identified outside authorised research. # #

Esketamine has EU and international trial evidence and is visible in Mexico's Compendio Nacional de Insumos para la Salud. That improves public-system legitimacy, but access still depends on local adoption, procurement, specialist administration and budgets. # # #

Ketamine is a Group III psychotropic with recognised therapeutic use. It can exist in ordinary controlled medical care, but depression treatment remains off-label, with public evidence strongest for a small Mexico City-linked clinical study. # # #

DMT is listed as a Group I psychotropic. Reviewed sources did not show an authorised treatment or reimbursement route outside health-authority-approved research. #

No approved Mexican medical pathway for 5-MeO-DMT was identified. Mexico-linked evidence comes mainly from private or naturalistic ibogaine plus 5-MeO-DMT observational work, not from national authorisation. #

Ibogaine is not an approved medicine in Mexico. Private clinics operate and have contributed observational evidence, especially in cross-border treatment settings, but this is not a recognised national treatment or reimbursement pathway. # #

Mexico controls DMT and reviewed sources did not identify a national medical or reimbursement route for ayahuasca. Ceremonial or cultural contexts should not be treated as general medical authorisation. #

Mescaline and peyote are listed in Group I. Wixarika sacred-route protection and the UNESCO inscription matter for Indigenous governance and peyote context, but they do not create a general medical access route. # # #

Reviewed Mexican sources did not identify an authorised treatment or reimbursement route for 2C-family substances. Any public claim should be checked against current controlled-substance language before publication. #